Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of Two Schedules of 4CMenB Vaccine
NCT02583412Phase 4Completed
- Sponsor
- Canadian Immunization Research Network
- Start
- Sep 2015
- Primary completion
- Sep 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of meningococcal group B vaccine in meningococcal group B infection (MenB) (2 arms), sponsored by Canadian Immunization Research Network. Primary endpoint: human Serum Bactericidal Assay at Day 180. Started Sep 2015; status: completed.
02
Drugs
meningococcal group B vaccine
03
Conditions
meningococcal group B infection (MenB)
Beyond the preview
Go deeper on NCT02583412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02583412.